Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59

Daratumumab (DARA) has improved the outcome of treatment of multiple myeloma (MM). DARA acts via complement-dependent and -independent mechanisms. Resistance to DARA may result from upregulation of the complement inhibitory proteins CD55 and CD59, downregulation of the DARA target CD38 on myeloma ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Kieran, Iversen, Katrine F., Blanco-Fernández, Alfonso, Lund, Thomas, Plesner, Torben, Mc Gee, Margaret M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658084/
https://www.ncbi.nlm.nih.gov/pubmed/36359760
http://dx.doi.org/10.3390/cells11213365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658084/
https://www.ncbi.nlm.nih.gov/pubmed/36359760
http://dx.doi.org/10.3390/cells11213365

Ejemplares similares